Rocket Lab USA, Inc.

The stock remains in a long-term uptrend that has pulled back sharply from its 52-week high of 151, but it still sits well above the 52-week low of 37.57. Price is below the 200-day average of 77.32, so the broader regime is still a recovery phase rather than a confirmed sustained breakout.

Street sentiment stays constructive, with a Buy consensus and a $108.78 average target versus a $66.39 share price. Recent calls are mixed at the margin: Piper Sandler started Neutral at $83, while several firms kept bullish ratings and lifted targets into the $120-$135 range.

The next print is set up against a choppy earnings record, with 3 beats in the last 7 quarters. Analysts still expect losses to narrow, with 2027 EPS near breakeven at 0.00616 and 2028 EPS at 0.23, so shareholders should watch margin progress and launch/system execution.

Recent insider activity is heavily skewed to selling, led by CEO Peter Beck with 15 sale transactions in early July. No insider buys appear in the period, and the pattern looks like concentrated monetization rather than offsetting accumulation.

Profitability remains negative, but the top line is growing fast. Revenue rose 63.5% year over year, while gross margin reached 36.6% and operating margin was -22.36%; the balance sheet is still strong with $1.02 billion in cash and $762.6 million in net cash.

RKLB trades as a higher-beta aerospace name with a 2.553 beta and a premium growth profile versus slower industrial peers. The setup favors valuation support from a $108.78 consensus target, but the stock still screens as expensive on current earnings with a negative EPS and no near-term profitability.